Regimen And Response To Chemotherapy On Laryngeal Non-Hodgkin Lymphoma
DOI:
https://doi.org/10.52783/jns.v14.3305Keywords:
Non-Hodgkin Lymphoma larynx, Chemotherapy, CHOP, COMP, Response to chemotherapyAbstract
Background: Non-Hodgkin Lymphoma (NHL) is a malignant neoplasm originating from lymphoid tissue, especially lymph
nodes. The incidence of NHL is 3% of all tumors in the head and neck area, 85% of malignant lymphoma are extranodal
NHL, and 1% of primary tumors originate from the larynx. Standard management of NHL is chemotherapy or combination
with radiotherapy.
Purpose: To report two rare cases of laryngeal NHL, the types of regimens, and their responses to chemotherapy.
Case Reports: Two cases of laryngeal NHL. The first case was a 58-year-old woman who gave a complete chemotherapy
response; the second was a 17-year-old boy who gave a complete chemotherapy response.
Treatment: Chemotherapy with six cycles of CHOP regimen (Cyclophosphamide, Oncovin, Doxorubicin, and Prednisone)
for the first case and 16 cycles of COMP regimen (Cyclophosphamide, Vincristine, Methotrexate and Prednisone) for the
second case.
Conclusion: Six cycles of chemotherapy using the CHOP regimen in adult patients and 16 cycles with the COMP regimen
in pediatric patients gave a complete chemotherapy response.
Downloads
Metrics
References
Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS, et al. Non Hodgkin’s lymphoma. Family Medicine
and Primary Care Wolters Kluwer Medknow 2020; 9(4):1834-40.
Pai A, Kannan T, Balambika RG, Vasini V. A study of clinical profile of primary extranodal lymphomas in a
tertiary care institute in south India. Indian Journal of Medical and Paediatric Oncology South India 2017;
(3):251.
Hong SA, Tajudeen BA, Sunnah C, Husain IA. Epidemiology and prognostic indicators in laryngeal lymphoma:
a population-based analysis. The American Laryngological, Rhinological and Otological Society 2018;
(9):2044-49.
Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment
of laryngeal carcinoma. Cancer Treat Rev 2006; 32(7):504–15.
Suna H, Li X, Guod Y, Due Y, Nana K, Li M. Global, regional and national burden of non-Hodgkin lymphoma
from 1990 to 2017: estimates from global burden of disease study in 2017. Annals of Medicine 2022; 54(1):633
International agency for research on cancer. 360 Indonesia Fact Sheet Globacon. 2020. Available from:
https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf. Accessed June 11, 2022.
Fadhlia, Kurnia B, Setiani L, Karnita Y, Juniar, Berliananda I. Characteristics of non-Hodgkin lymphoma
patients in otorhinolaryngology-hns department Zainoel Abidin general hospital Banda Aceh.
Otorhinolaryngology Head and Neck Surgery Department Medical Faculty of Syiah Kuala Universit /dr.
Zainoel Abidin General Hospital Banda Aceh 2020; 50(1):46-51.
Setioyohadi B, Sudoyo A, Alwi I, Simadibrata M, Setiati S. Limfoma non-Hodgkin. Dalam: Reksodiputro A,
Irawan C, ed. Buku ajar ilmu penyakit dalam Jilid I. Edisi keempat. Jakarta: Pusat Penerbitan Ilmu Penyakit
Dalam; 2003. hal. 717–23.
Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer Journal for Clinicians 2015; 55:368-76.
Journal of Neonatal Surgery | Year: 2025 | Volume: 14 | Issue: 13s
pg. 566
Sapta Faradillah, Muhtarum Yusuf
Miller TP. Management of intermediate grade lymphomas. Oncology Journal 2018;12:10. Available from:
http://www.cancernetwork.com/review-article/management-intermediate-grade-lymphomas Accessed Nov 22,
Jeong JU, Chung WK, Nam TK, Yang DH, Ahn SJ, Song JY, et al. Treatment results of radiotherapy following
CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional
experience. Radiat Oncol J 2017;35(4):317–24.
Oers MHJV, Glabbeke MV, Klasa R, Giurgea L, Klasa R, at al. Rituximab maintenance treatment of
relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the eortc 20981 phase III
randomized intergroup study. Journal of Clinical Oncology 2010; 28(17):2853-58.
Chaker K, Beghdad M, Mennouni MA, Mkhatri A, Oukessoub Y, Mahtar M. Primary laryngeal t-cell
lymphoma: a case report and review of the literature. International Journal of Surgery Case Reports
;82:2210-12.
Cavalot AL, Preti G, Vione N, Nazionale G, Palonta F, Fadda GL. Isolated primary non-Hodgkin’s malignant
lymphoma of the larynx. The Journal of Laryngology & Otology 2001; 115: 324-26.
Ayyaswamy A, Saravanam PK, Latha S, Sundaram S. Laryngeal lymphoma in a child – case report and review
of literature. Iranian Journal of Otorhinolaryngology 2022; 34(6):2-4.
Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. Cardiotoxicity with rituximab,
cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisolone in frontline treatment of patients with diffuse
large b-cell lymphoma: a randomised phase-III study from the Austrian cancer drug therapy working group
[arbeitsgemeinschaft medikamentöse gumortherapie agmt] (nhl-14). Eur Journal Cancer 2016; 58:112-21.
Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate,
vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patientswith
refractory or recurrent acute lymphoblastic leukemia. The American Cancer Society 2000; 86(7):1203-09.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria
in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–47.
Seifter EJ. Adult non-hodgkin lymphoma treatment. The National Institutes of Health 2022. p. 1-34. Avalaible
from : https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed November 28,
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
